<DOC>
	<DOCNO>NCT00020605</DOCNO>
	<brief_summary>RATIONALE : Naloxone may effective treat constipation may cause opioid pain medication morphine . PURPOSE : Phase III trial determine effectiveness naloxone relieve constiption patient receive opioids chronic pain .</brief_summary>
	<brief_title>Naloxone Treating Constipation Patients Who Are Receiving Opioids Chronic Pain</brief_title>
	<detailed_description>OBJECTIVES : I. Assess long-term safety efficacy oral naloxone treat opioid-induced constipation patient chronic malignant non-malignant pain . OUTLINE : This multicenter study . Patients receive oral naloxone twice daily . Each patient receive escalate dose minimum effective dose maximum dose allow reach . The minimum effective dose define dose patient least 4 bowel movement within 7 day . Patients receive minimum effective dose 7 day continue long-term treatment maximum 72 week . Patients receive maximum dose allow few 4 bowel movement per week discontinue study therapy . PROJECTED ACCRUAL : Approximately 600 patient accrue study .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Intestinal Obstruction</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Moderate severe opioidinduced constipation Previously enrol protocol NAL0396 , NAL0397 , and/or NAL0398 OR Low frequency bowel movement , define few 3 per week past 2 week , AND either follow : Score `` '' , `` quite bit '' , `` much '' constipation distress scale Laxative enema dependence Daily opioid intake equivalent least 30 mg oral morphine chronic pain malignant nonmalignant origin Stable dose opioid analgesic agent least 2 week No score `` excruciate '' verbal pain scale No history partial complete bowel obstruction No constipation secondary factor opioids ( e.g. , autonomic neuropathy intraabdominal adhesion ) PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Potassium normal Other : No uncontrolled endocrinopathy diabetes No psychiatric disorder encephalopathy would preclude study No clinically significant medical condition would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Concurrent chemotherapy allow provided patient complete least 1 course prior study Endocrine therapy : Concurrent hormonal therapy allow provided dosage stable least 2 week prior study Radiotherapy : No concurrent palliative radiotherapy spine , abdomen , pelvic area Surgery : Not specify Other : At least 30 day since investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2001</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>constipation , impaction , bowel obstruction</keyword>
</DOC>